Griet Vanpoucke

Montis’ mission is to therapeutically exploit cellular interactions between perivascular macrophages and tumor vasculature to drive and sustain immune reactions against solid tumors. Montis was founded based on the foundational science from the laboratories of Prof. Peter Carmeliet and Massimiliano Mazzone (VIB-KU Leuven), and is backed by an international syndicate of investors.

Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.

Aelin Therapeutics is a privately held Belgian biotechnology company, pioneering a novel modality in drug development. Using our Pept-in platform technology, we can create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Montis’ mission is to therapeutically exploit cellular interactions between perivascular macrophages and tumor vasculature to drive and sustain immune reactions against solid tumors. Montis was founded based on the foundational science from the laboratories of Prof. Peter Carmeliet and Massimiliano Mazzone (VIB-KU Leuven), and is backed by an international syndicate of investors.

Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.

VIB is a pioneering life sciences research institute where curiosity and collaboration drive bold, fundamental science. Since 1996, we have combined cutting-edge biomolecular research with a strong commitment to making a real impact on society. Our mission is clear: to expand scientific knowledge and improve people’s lives. At VIB, diverse and driven minds from multiple disciplines come together to explore the fundamental workings of life, human health, and disease. We believe that groundbreaking discoveries happen when people are given freedom, support, and trust to challenge themselves, and each other. 𝐖𝐞 𝐩𝐮𝐬𝐡 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐟𝐨𝐫𝐰𝐚𝐫𝐝. We conduct bold, curiosity-driven research to expand the frontiers of life sciences. 𝐖𝐞 𝐠𝐫𝐨𝐰 𝐛𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐨𝐮𝐫𝐬𝐞𝐥𝐯𝐞𝐬. VIB offers strong technical support, while encouraging ownership and ambition. Yes, the bar is high, but so is our motivation. We know what we’re striving for and why it matters. 𝐖𝐞 𝐰𝐨𝐫𝐤 𝐭𝐨𝐠𝐞𝐭𝐡𝐞𝐫 𝐭𝐨 𝐦𝐚𝐤𝐞 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞. We share knowledge, value diversity and foster and inclusive culture. Our impact extends beyond the lab, we bring science to society. Rooted in close partnerships with five Flemish universities (Ghent, KU Leuven, Antwerp, VUB, and UHasselt) and backed by solid funding, VIB is a vibrant ecosystem where science and people thrive. Follow VIB for groundbreaking discoveries and career opportunities or join us to help shape the future of life sciences. 𝐅𝐨𝐫 𝐣𝐨𝐛 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 > 𝐣𝐨𝐛𝐬.𝐯𝐢𝐛.𝐛𝐞

Aelin Therapeutics is a privately held Belgian biotechnology company, pioneering a novel modality in drug development. Using our Pept-in platform technology, we can create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.